CinCor Pharma Raises $143 Million in Series B Financing to Advance Aldosterone Synthase Inhibitor for Cardio-Renal Diseases

CinCor Pharma Raises $143 Million in Series B Financing to Advance Aldosterone Synthase Inhibitor for Cardio-Renal Diseases

CinCor Pharma announced the completion of a $143 million Series B financing. The financing was led by General Atlantic, with participation from new investors Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, and Sixty Degree Capital. Also participating were existing investors Sofinnova Investments, Sofinnova Partners, 5AM Ventures, and CinRx. The proceeds from this round will support the continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate in development for the treatment of hypertension, primary aldosteronism, and chronic kidney disease. 

“This financing will enable us to obtain the data that we hope will establish that aldosterone synthesis inhibition is a potent approach to lowering blood pressure in several patient groups, including individuals with hypertension demonstrated to be resistant to existing treatment options,” said Marc de Garidel, Chief Executive Officer of CinCor. “In addition, it will enable us to continue to obtain data that may expand the potential utility of CIN-107 into other indicati...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee